Patents by Inventor Lianshan Zhang

Lianshan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170020963
    Abstract: Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15R? heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15R? or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.
    Type: Application
    Filed: December 25, 2014
    Publication date: January 26, 2017
    Inventors: Xiangdong QU, Xin YE, Jijun YUAN, Lei ZHANG, Kan CHEN, Lianshan ZHANG, Guoqing CAO, Zhibin XU, Weikang TAO
  • Publication number: 20170002090
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Application
    Filed: January 22, 2015
    Publication date: January 5, 2017
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali WANG, Lianshan ZHANG, Jindong LIANG, Ang LI, Fanglong YANG
  • Publication number: 20160376367
    Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.
    Type: Application
    Filed: November 14, 2014
    Publication date: December 29, 2016
    Applicant: Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jijun Yuan, Xiangdong Qu, Jufang Lin, Xin Ye, Guoqing Cao, Weikang Tao, Lianshan Zhang, Lei Zhang, Li Yang
  • Publication number: 20160326230
    Abstract: Disclosed are a human relaxin analogue, a polynucleotide encoding the human relaxin analogue, a pharmaceutical composition comprising the human relaxin analogue, and a pharmaceutical application of the human relaxin analogue. Also disclosed is a derivative of the human relaxin analogue.
    Type: Application
    Filed: October 10, 2014
    Publication date: November 10, 2016
    Inventors: Lianshan ZHANG, Jiajian LIU, Guoqing CAO
  • Publication number: 20160289321
    Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
    Type: Application
    Filed: October 27, 2014
    Publication date: October 6, 2016
    Applicants: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Lianshan ZHANG, Jiajian LIU, Guoqing CAO, Piaoyang SUN
  • Patent number: 9458219
    Abstract: The present invention provides a human insulin analog, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analog and an application of the insulin analog as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: October 4, 2016
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Piaoyang Sun, Lianshan Zhang, Jiajian Liu, Jijun Yuan, Chunqian Fang, Changan Sun, Hengli Yuan, Yali Wang
  • Publication number: 20160051688
    Abstract: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Application
    Filed: August 28, 2015
    Publication date: February 25, 2016
    Inventors: Richard D. DiMARCHI, Lianshan ZHANG
  • Publication number: 20150297681
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: May 1, 2015
    Publication date: October 22, 2015
    Applicant: ELI LILLY AND COMPANY
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Ryan John Hansen, Shun Li, Lianshan Zhang, Brandon Doyle, Shahriar Shirani
  • Patent number: 9145451
    Abstract: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: September 29, 2015
    Assignees: Indiana University Research and Technology Corporation, Marcadia Biotech, Inc.
    Inventors: Richard D. DiMarchi, Lianshan Zhang
  • Patent number: 9090568
    Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: July 28, 2015
    Assignee: IMPACT Therapeutics, Inc.
    Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
  • Patent number: 9050371
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: June 9, 2015
    Assignee: Eli Lilly and Company
    Inventors: John Michael Beals, Gordon Butler Cutler, Jr., Ryan John Hansen, Shun Li, Lianshan Zhang
  • Publication number: 20140329745
    Abstract: The present invention provides a human insulin analogue, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analogue and an application of the insulin analogue as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.
    Type: Application
    Filed: November 22, 2012
    Publication date: November 6, 2014
    Inventors: Piaoyang Sun, Lianshan Zhang, Jiajian Liu, Jijun Yuan, Chunqian Fang, Changan Sun, Hengli Yuan, Yali Wang
  • Publication number: 20140031358
    Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.
    Type: Application
    Filed: March 12, 2012
    Publication date: January 30, 2014
    Applicant: Eternity Bioscience Inc.
    Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
  • Publication number: 20130116172
    Abstract: Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 9, 2013
    Applicant: MARCADIA BIOTECH, INC.
    Inventors: Richard D. Dimarchi, Lianshan Zhang
  • Patent number: 8183340
    Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: May 22, 2012
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
  • Publication number: 20110105392
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: June 9, 2009
    Publication date: May 5, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Brandon Lee Doyle, Ryan John Hansen, Shun Li, Shahriar Shirani, Lianshan Zhang
  • Patent number: 7897573
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Publication number: 20100048460
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: February 26, 2007
    Publication date: February 25, 2010
    Inventors: Lianshan Zhang, Jorge Alsina-Fernandez
  • Publication number: 20100009916
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: July 24, 2009
    Publication date: January 14, 2010
    Inventors: BENGT KRISTER BOKVIST, LIANSHAN ZHANG, JORGE ALSINA-FERNANDEZ
  • Publication number: 20090312236
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: June 9, 2009
    Publication date: December 17, 2009
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Brandon Doyle, Ryan John Hansen, Shun Li, Sean Shirani, Lianshan Zhang